A Prospective, Observational Study of Real-World Efficacy and Patient-Reported Quality of Life
- Study HIC#:2000026739
- Last Updated:04/26/2024
To evaluate patient-reported health-related quality of life outcomes in subjects with RRMM treated with daratumumab-based regimens in a real life setting.
Contact Us
For more information about this study, including how to volunteer, contact:
Christopher Walsh
- Phone Number: 1-203-737-8897
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
To evaluate the overall clinical response rate.To evaluate time to next treatment. To evaluate the line of therapy in which daratumumab is used. To evaluate the pattern and choice of a regimen in which daratumumab is used: single-agent versus combinations. To evaluate bone health, pain, and mobility of patients. To evaluate the overall safety and rate of adverse events of daratumumab regimens in a real life setting. To evaluate the rate of daratumumab infusion-related adverse events.Evaluate the rate of discontinuation of daratumumab in real life setting. To evaluate investigator-assessed PFS and OS.
